The use of prophylactic furazolidone to control a nosocomial epidemic of multiply resistant Salmonella typhimurium in pediatric wards. Pediatr Infect Dis J 9:551-555
Division of Pediatrics, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.The Pediatric Infectious Disease Journal (Impact Factor: 2.72). 09/1990; 9(8):551-5. DOI: 10.1097/00006454-199008000-00005
The nosocomial spread of enteric pathogens is often difficult to control in overcrowded pediatric wards. During 1983 and 1984, despite cohorting of patients and enforced hand washing, more than 200 cases of nosocomial multiply resistant Salmonella typhimurium phage type R-9 were observed on two adjacent pediatric wards. Most cases occurred during the summer months. After 19 new cases were detected early in the summer of 1985, oral administration of furazolidone throughout their entire hospital stay (2.5 mg/kg twice daily) was recommended for all subsequently hospitalized infants. Among the 114 (65%) infants who were appropriately treated, only one additional case (1%) was detected. In contrast 11 (19%) cases occurred among the 59 infants who were inappropriately treated: 5 of 35 (14%) of those who were not treated and 6 of 24 (25%) in whom treatment with furazolidone was delayed greater than 24 hours (P less than 0.001 between the appropriately and inappropriately treated groups). In pediatric wards where infection control measures cannot be optimally applied, prophylactic furazolidone administration may be helpful in preventing the spread of enteric pathogens.
Article: Les salmonelloses en pédiatrie[Show abstract] [Hide abstract]
ABSTRACT: Fifty per cent of Salmonella infectious occur in childhood and especially before the age of two years (50 %). In industrialized countries, there are no more outbreaks in pediatrics wards or day-care centers. Infections are observed all the year and S. typhimurium is always the main serotype. A striking feature in childhood is the high frequency of bacteriemias. Complications (meningitis, joint or bone infections) occur in “high-risk” children (neo-nates and infants, sickle cell disease, immunodeficiencies). Systematic treatment in this children is advocated with the same antibiotics as in adults, except for fluoroquinolones.MÃ©decine et Maladies Infectieuses 03/1992; 22:299-309. DOI:10.1016/S0399-077X(05)80135-0 · 1.24 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: From January, 1990, to December 31, 1990, 75 children with multiply resistant Salmonella gastroenteritis were studied at the Children's Hospital "Ricardo Gutierrez" of Buenos Aires. These children ranged from 1 month to 15 years of age. Infection was community-acquired in 20 (26.6%), nosocomially acquired in 50 (66.7%) and undetermined in 5. Thirty-nine (52%) had grossly bloody stools. Fever occurred at some point in the clinical course in 61 children (81.3%) with a duration of 1 to 33 days (mean, 6.7 days). The duration of diarrhea (1 to 69 days) was longer in those who developed complications (P < 0.001). Six (8%) developed enterocolitis (2 with bowel perforation), 1 had a pulmonary abscess and 8 (11.4%) had bacteremia; 4 children died (5.3%). Salmonella typhimurium was the most common serovar (85.3%). Ninety percent minimum inhibitory concentration studies demonstrated that all strains were resistant to ampicillin (> 128 micrograms/ml), cephalothin (> 128 micrograms/ml), cefuroxime (> 128 micrograms/ml), nalidixic acid (> 256 micrograms/ml), rifampin (> 256 micrograms/ml), gentamicin (> 256 micrograms/ml) and tobramycin (256 micrograms/ml); 77.3% of strains were resistant to ceftazidime (32 micrograms/ml), 97.6% to netilmicin (> 256 micrograms/ml), 92.8% to amikacin (256 micrograms/ml), 24.4% to isepamicin (32 micrograms/ml), 5.3% to chloramphenicol (4 micrograms/ml) and 2.7% to cefoxitin (2 micrograms/ml). The 90% minimum inhibitory concentration of cefotaxime and ceftazidime was reduced by the addition of clavulanate. Aggressive multiply resistant Salmonella strains are a major pediatric problem in Buenos Aires.The Pediatric Infectious Disease Journal 02/1993; 12(2):139-45. DOI:10.1097/00006454-199302000-00007 · 2.72 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Antimicrobial resistance is common and clearly is increasing in frequency in clinically important enteropathogens. Antibiotic resistance often is associated with greater morbidity and mortality because it leads to delay in the initiation of adequate therapy. More prudent use of antibiotics, both for diarrheal disease and other infections, would decrease the frequency of these strains. At present, if a strain of Salmonella species, Shigella species, or diarrhea-associated E coli is multidrug-resistant, it is still likely to be susceptible to third-generation cephalosporins or ciprofloxacin.Seminars in Pediatric Infections Diseases 07/1996; 7(3-7):212-222. DOI:10.1016/S1045-1870(96)80009-4
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.